Genomics drug design/discovery

Dean, P.M., et al., "Industrial-Scale, Genomics-Based Drug Design and Discovery," Trends Biotechnol., 19, 288-292 (2001). 

Meyer B. STD NMR to screen libraries and characterize binding, in NMR drug discovery and design - Post-genomic analysis. 2000. McLean, Virginia Cambridge Healthtech Institute. 

With the help of an international authorship, we have attempted to cover major aspects of lipase research, from genomics to drug discovery via validation of targets, structural biology, rational drug design, and drug-hpase interaction. 

The processes as just described do not require any information coordination between the genomics and proteomics work and the subsequent lead discovery and optimization. In the last decade, there has been a growing effort to transition the information from the proteomics step into a computer-aided dmg discovery process—to use the information about the protein itself to help choose appropriate compounds to screen for the desired efficacy. The use of computers to assist in drug discovery neither is new nor was always tied to the use of protein structures. The recent developments in proteomics have focused the work on protein structure-based computer-aided drug design. 

Current Achievements and Potential Application of Genomics and Proteomics in Drug Design and Discovery 565... 

CURRENT ACHIEVEMENTS AND POTENTIAL APPLICATION OF GENOMICS AND PROTEOMICS IN DRUG DESIGN AND DISCOVERY... 

---